Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

Abstract Coronavirus Disease‐19 (COVID‐19) is an infectious disease caused by severe
acute respiratory syndrome‐coronaviruses‐2 (SARS‐CoV‐2), a highly pathogenic and …

Highlights•The main protease, known as M pro, is encoded by the viral genome and is
essential for viral replication.•The effective target for drug development has been the M …

While vaccines remain at the forefront of global healthcare responses, pioneering
therapeutics against SARS-CoV-2 are expected to fill the gaps for waning immunity. Rapid …

Emerging variants of SARS‐CoV‐2 and potential novel epidemic coronaviruses underline
the importance of investigating various viral proteins as potential drug targets. The papain …

Abstract SARS-CoV-2 main protease (M pro) is a validated antiviral drug target of
nirmatrelvir, the active ingredient in Pfizer's oral drug Paxlovid. Drug-drug interactions limit …

The current pandemic caused by the COVID-19 disease has reached everywhere in the
world and has affected every aspect of our lives. As of the current data, the World Health …

The emergence of SARS-CoV-2 variants and drug-resistant mutants calls for additional oral
antivirals. The SARS-CoV-2 papain-like protease (PLpro) is a promising but challenging …

The two proteases, PLpro and Mpro, of SARS-CoV-2 are essential for replication of the virus.
Using a structure-based co-pharmacophore screening approach, we developed a novel …